RAPH · Raphael Pharmaceutical Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“We do not believe that our current cash on hand will be sufficient to fund our projected operating requirements. This raises substantial doubt about our ability to continue as a going concern. At this time, there is no guarantee that we will be able to obtain an adequate level of financial resources required for the short and long-term support of our operations or that we will be able to obtain additional financing as needed, or meet the conditions of such financing, or that the costs of such financing may not be prohibitive. These conditions raise substantial doubt about our ability to continue as a going concern for a period within one year from the date of the financial statements included elsewhere in this Quarterly Report.”View the 10-Q filed Aug 14, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $495K | $631K | $776K | $569K | $1.18M | $776K | $461K | |
| $432K | $614K | $733K | $763K | $2.14M | $853K | $245K | |
| -$927K | -$1.25M | -$1.51M | -$1.33M | -$3.32M | -$1.63M | -$706K | |
| -$53K | -$34K | -$10K | -$12K | -$41K | $4000 | -$12K | |
| -$980K | -$1.28M | -$1.52M | -$1.34M | -$3.36M | -$1.63M | -$718K | |
| — | — | — | -$1.28M | -$3.36M | -$1.63M | -$718K | |
| — | — | — | — | $3.36M | $1.63M | -$718K | |
| USD/shares | $0.05 | $0.07 | $0.08 | $0.08 | $0.23 | $0.15 | — |
| USD/shares | $0.05 | $0.07 | $0.08 | $0.08 | $0.23 | $0.15 | — |
| shares | — | 19.55M | 18.67M | 16.72M | 14.34M | 11.17M | 9.46M |
| shares | — | 19.55M | 18.67M | 16.72M | 14.34M | 11.17M | 9.46M |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current portion of notes payable | 2024-12-31 | USD 228,000 | 10-K filed 2025-03-31 |
| Short-term borrowings | 2024-12-31 | ILS 150,000 | 10-K filed 2025-03-31 |
| Short-term borrowings | 2024-12-31 | USD 41,000 | 10-K filed 2025-03-31 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 42 similar-size Drug Manufacturers - Specialty & Generic companies (of 101 listed).